In a research report published Thursday, H.C.
Roth Capital analyst Ed Arce maintained a Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a $20 price target, following the news that the FDA …
Over the past four years, the S&P 500 has increased a total of 66%. However, the Biotech sector outperformed the S&P 500 by …
MLV’s healthcare analyst Vernon Bernardino today weighed in with his thoughts on BioCryst Pharmaceuticals (NASDAQ:BCRX), as the company announced positive results from evaluation of its broad spectrum …
In a research note issued today, analyst Vernon Bernardino of MLV reiterated a Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a price target of $15, …
In a research report issued today, Roth Capital analyst Ed Arce reiterated a Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a $20 price target, …
In a research report issued Friday, Roth Capital analyst Ed Arce maintained a Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a $20 price …
In a research report issued Friday, Roth Capital analyst Ed Arce reiterated a Buy rating on BioCryst Pharmaceuticals (NASDAQ: BCRX) with a price target …
BioCryst Pharmaceuticals (BCRX) today announced the National Institute of Allergy and Infectious Diseases (NIAID) has exercised additional options to conduct Phase I clinical human safety …
In a research note issued August 6, Roth Capital analyst Ed Arce reiterated a Buy rating on BioCryst Pharmaceuticals (BCRX) with a $20 …
